GEP20146064B - 3-minocyclopentanecarboxamides as chemokine receptor modulators - Google Patents

3-minocyclopentanecarboxamides as chemokine receptor modulators

Info

Publication number
GEP20146064B
GEP20146064B GEAP200912239A GEAP2009012239A GEP20146064B GE P20146064 B GEP20146064 B GE P20146064B GE AP200912239 A GEAP200912239 A GE AP200912239A GE AP2009012239 A GEAP2009012239 A GE AP2009012239A GE P20146064 B GEP20146064 B GE P20146064B
Authority
GE
Georgia
Prior art keywords
chemokine receptor
minocyclopentanecarboxamides
receptor modulators
ted
atherosclerosis
Prior art date
Application number
GEAP200912239A
Other languages
English (en)
Inventor
Steve Ronald Turner
John Isidro Trujillo
Jr Donald Joseph Rogier
Robert Owen Hughes
Wei Huang
Rajesh Venkateswaran Devraj
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of GEP20146064B publication Critical patent/GEP20146064B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
GEAP200912239A 2008-11-26 2009-11-20 3-minocyclopentanecarboxamides as chemokine receptor modulators GEP20146064B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11805308P 2008-11-26 2008-11-26

Publications (1)

Publication Number Publication Date
GEP20146064B true GEP20146064B (en) 2014-03-25

Family

ID=41693100

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP200912239A GEP20146064B (en) 2008-11-26 2009-11-20 3-minocyclopentanecarboxamides as chemokine receptor modulators

Country Status (38)

Country Link
US (2) US8293903B2 (enExample)
EP (1) EP2370442B9 (enExample)
JP (1) JP5108153B2 (enExample)
KR (1) KR101374412B1 (enExample)
CN (1) CN102227429B (enExample)
AP (1) AP3113A (enExample)
AU (1) AU2009321221B2 (enExample)
BR (1) BRPI0920936A2 (enExample)
CA (1) CA2743030C (enExample)
CL (1) CL2011001223A1 (enExample)
CO (1) CO6361921A2 (enExample)
CR (1) CR20110275A (enExample)
CU (1) CU24022B1 (enExample)
CY (1) CY1114020T1 (enExample)
DK (1) DK2370442T5 (enExample)
DO (1) DOP2011000154A (enExample)
EA (1) EA020470B1 (enExample)
EC (1) ECSP11011081A (enExample)
ES (1) ES2415430T3 (enExample)
GE (1) GEP20146064B (enExample)
HR (1) HRP20130409T2 (enExample)
IL (1) IL212732A (enExample)
MA (1) MA32834B1 (enExample)
ME (1) ME01144B (enExample)
MX (1) MX2011005526A (enExample)
MY (1) MY152557A (enExample)
NI (1) NI201100102A (enExample)
NZ (1) NZ592919A (enExample)
PE (1) PE20110831A1 (enExample)
PL (1) PL2370442T3 (enExample)
PT (1) PT2370442E (enExample)
RS (2) RS52810B9 (enExample)
SI (1) SI2370442T1 (enExample)
SV (1) SV2011003923A (enExample)
TN (1) TN2011000254A1 (enExample)
UA (1) UA99978C2 (enExample)
WO (1) WO2010061329A1 (enExample)
ZA (1) ZA201104069B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370442B9 (en) * 2008-11-26 2013-09-04 Pfizer Inc. 3-Aminocyclopentanecarboxamides as chemokine receptor modulators
KR101303963B1 (ko) * 2011-04-08 2013-09-05 재단법인 경기과학기술진흥원 (1r,2r,3r)-3-아미노사이클로펜탄-1,2-디올을 포함하는 항알러지용 조성물
AU2015240465B2 (en) 2014-04-04 2020-02-27 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
TW201605451A (zh) * 2014-07-17 2016-02-16 參天製藥股份有限公司 老年性黃斑部病變之預防或治療劑
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
TWI830733B (zh) * 2018-05-11 2024-02-01 中國大陸商迪哲(江蘇)醫藥有限公司 環戊烷化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
AU2964295A (en) 1994-07-11 1996-02-09 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
US5462208A (en) 1994-08-01 1995-10-31 The Procter & Gamble Company Two-phase dispensing systems utilizing bellows pumps
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996031206A2 (en) 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
US5704960A (en) 1995-12-20 1998-01-06 Corning, Inc. Method of forming an optical fiber for reduced polarization effects in amplifiers
GB9603741D0 (en) 1996-02-22 1996-04-24 Lin Mei Treatment of water by electrolysis
JP2000516210A (ja) 1996-07-12 2000-12-05 ロイコサイト,インコーポレーテッド ケモカインレセプターアンタゴニストとその使用方法
WO1998042656A1 (en) 1997-03-21 1998-10-01 Cytel Corporation Novel compounds
ES2257808T3 (es) 1997-05-29 2006-08-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Acidos biarilalcanoicos como inhibidores de adhesion celular.
AU728435B2 (en) 1997-05-29 2001-01-11 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
CA2291778A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
ATE256699T1 (de) 1997-05-30 2004-01-15 Celltech Therapeutics Ltd Entzündungshemmende tyrosin-derivate
PT991619E (pt) 1997-06-23 2004-02-27 Upjohn Co Inibidores da adesao celular mediada pela alfa4beta1
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
JO2479B1 (en) 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
DK1501507T3 (da) * 2002-04-29 2008-09-29 Merck & Co Inc Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
GEP20084505B (en) 2003-12-18 2008-10-10 Incyte Corp 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
AU2005219438B2 (en) * 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
JP2007534755A (ja) 2004-04-28 2007-11-29 メルク エンド カムパニー インコーポレーテッド ケモカイン受容体活性のモジュレーターとなる3,3−ジ置換テトラヒドロピラニルシクロペンチルアミド
EP1763347A4 (en) * 2004-06-28 2009-05-20 Incyte Corp 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS
CN1976707A (zh) * 2004-06-28 2007-06-06 因赛特公司 作为趋化因子受体调节剂的3-氨基环戊烷甲酰胺类
AP2006003849A0 (en) 2004-06-28 2006-12-31 Incyte Corp 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
MEP1008A (xx) 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
EP2370442B9 (en) * 2008-11-26 2013-09-04 Pfizer Inc. 3-Aminocyclopentanecarboxamides as chemokine receptor modulators

Also Published As

Publication number Publication date
ES2415430T9 (es) 2013-11-25
MY152557A (en) 2014-10-31
RS52810B (en) 2013-10-31
WO2010061329A1 (en) 2010-06-03
MX2011005526A (es) 2011-06-06
HRP20130409T1 (en) 2013-06-30
NI201100102A (es) 2011-09-27
KR101374412B1 (ko) 2014-03-17
HK1161261A1 (en) 2012-08-24
SI2370442T1 (sl) 2013-06-28
IL212732A0 (en) 2011-07-31
US20130197008A1 (en) 2013-08-01
DK2370442T5 (da) 2013-09-23
AU2009321221A1 (en) 2010-06-03
PT2370442E (pt) 2013-06-27
AP2011005732A0 (en) 2011-06-30
JP2012509931A (ja) 2012-04-26
JP5108153B2 (ja) 2012-12-26
ES2415430T3 (es) 2013-07-25
CN102227429A (zh) 2011-10-26
RS52810B8 (sr) 2019-08-30
NZ592919A (en) 2013-05-31
EP2370442A1 (en) 2011-10-05
US8946413B2 (en) 2015-02-03
US8293903B2 (en) 2012-10-23
ME01144B (me) 2013-03-20
DK2370442T3 (da) 2013-06-17
EP2370442B9 (en) 2013-09-04
EA020470B1 (ru) 2014-11-28
CU24022B1 (es) 2014-07-30
CN102227429B (zh) 2014-05-28
PL2370442T3 (pl) 2013-08-30
US20110144129A1 (en) 2011-06-16
CU20110121A7 (es) 2013-05-31
SV2011003923A (es) 2011-07-28
TN2011000254A1 (fr) 2012-12-17
CO6361921A2 (es) 2012-01-20
PE20110831A1 (es) 2011-11-20
UA99978C2 (en) 2012-10-25
CR20110275A (es) 2011-07-01
AP3113A (en) 2015-01-31
CA2743030A1 (en) 2010-06-03
CY1114020T1 (el) 2016-07-27
IL212732A (en) 2016-06-30
KR20110075036A (ko) 2011-07-05
ECSP11011081A (es) 2011-12-30
DOP2011000154A (es) 2011-07-31
CA2743030C (en) 2013-10-22
CL2011001223A1 (es) 2011-09-02
RS52810B9 (sr) 2019-06-28
MA32834B1 (fr) 2011-11-01
ZA201104069B (en) 2012-02-29
AU2009321221B2 (en) 2013-04-04
EA201170721A1 (ru) 2011-12-30
EP2370442B1 (en) 2013-04-24
BRPI0920936A2 (pt) 2020-08-11
HRP20130409T2 (hr) 2013-11-22

Similar Documents

Publication Publication Date Title
TW200806300A (en) New therapeutic combinations for the treatment of depression
GEP20125704B (en) Plk kinase inhibitors
MX2009011997A (es) Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos.
GEP20217329B (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
TW200738242A (en) Dihydropteridinones in the treatment of respiratory diseases
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
GEP20125666B (en) HYDROXYMETHYL PYRROLIDINES AS β3 ADRENERGIC RECEPTOR AGONISTS
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
GEP20156368B (en) Non-nucleoside reverse transcriptase inhibitors
GEP20186838B (en) 5-phenoxy-3h-pyrimidin-4-one derivatives and their usage as hiv reverse transcriptase inhibitors
TW200833328A (en) 2-aza-bicyclo[3.1.0]hexane derivatives
GEP20156351B (en) Glucagon receptor modulator
TW200716628A (en) Novel compounds
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
GB0625648D0 (en) Compounds
MX2011006843A (es) Dihidropiridona-amidas como moduladores de p2x7.
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
GEP20146064B (en) 3-minocyclopentanecarboxamides as chemokine receptor modulators
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
GEP20135927B (en) 1-benzyl-3-hydroxymethylindaz-ole derivatives and usage thereat treatment of diseases based on mcp-1, cx3cr1 and p40 expression
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
MX2009013501A (es) Compuestos piperidinicos y sus usos.